Impact of COVID-19 on neurological patients attending a botulinum toxin service

Neurol Sci. 2021 Feb;42(2):433-435. doi: 10.1007/s10072-020-04940-2. Epub 2020 Nov 26.

Authors

Roberto Erro¹, Sara Scannapieco², Maria Russo², Marina Picillo², Paolo Barone²

Affiliations

¹ Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Via Allende, Baronissi, SA, Italy. rerro@unisa.it.
² Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Via Allende, Baronissi, SA, Italy.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Botulinum Toxins / therapeutic use*
COVID-19*
Case-Control Studies
Dystonia / drug therapy
Female
Health Status*
Humans
Italy
Male
Middle Aged
Migraine Disorders / drug therapy
Muscle Spasticity / drug therapy
Neuromuscular Agents / therapeutic use*
Quarantine
SARS-CoV-2
Time-to-Treatment*

Substances

Neuromuscular Agents
Botulinum Toxins